
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2109243/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of Systemic Lupus Erythematosus with <i>C8orf13–BLK</i> and <i>ITGAM–ITGAX</i> . New England Journal of Medicine, 2008, 358, 900-909.	27.0	848
2	Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nature Genetics, 2015, 47, 1457-1464.	21.4	730
3	Polymorphisms in the Tyrosine Kinase 2 and Interferon Regulatory Factor 5 Genes Are Associated with Systemic Lupus Erythematosus. American Journal of Human Genetics, 2005, 76, 528-537.	6.2	526
4	Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis and Rheumatism, 2004, 50, 1861-1872.	6.7	479
5	Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nature Genetics, 2013, 45, 1284-1292.	21.4	427
6	Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus, 2000, 9, 664-671.	1.6	402
7	FcÎ ³ RIIa Is Expressed on Natural IFN-α-Producing Cells (Plasmacytoid Dendritic Cells) and Is Required for the IFN-α Production Induced by Apoptotic Cells Combined with Lupus IgG. Journal of Immunology, 2003, 171, 3296-3302.	0.8	349
8	Activation of the type I interferon system in primary Sjögren's syndrome: A possible etiopathogenic mechanism. Arthritis and Rheumatism, 2005, 52, 1185-1195.	6.7	332
9	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	12.8	314
10	The type I interferon system in systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 408-420.	6.7	307
11	Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. Nature Genetics, 2016, 48, 940-946.	21.4	283
12	The innate immune system in SLE: type I interferons and dendritic cells. Lupus, 2008, 17, 394-399.	1.6	262
13	A Pivotal Role for the Natural Interferon α–producing Cells (Plasmacytoid Dendritic Cells) in the Pathogenesis of Lupus. Journal of Experimental Medicine, 2001, 194, F59-F64.	8.5	261
14	The interferon signature in autoimmune diseases. Current Opinion in Rheumatology, 2013, 25, 248-253.	4.3	258
15	Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. Journal of Immunology, 1999, 163, 6306-13.	0.8	219
16	Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clinical and Experimental Immunology, 1999, 115, 196-202.	2.6	216
17	Presence of cutaneous interferon-a producing cells in patients with systemic lupus erythematosus. Lupus, 2001, 10, 484-490.	1.6	209
18	Patients with Systemic Lupus Erythematosus have Reduced Numbers of Circulating Natural Interferon-α- Producing Cells. Journal of Autoimmunity, 1998, 11, 465-470.	6.5	198

#	Article	IF	CITATIONS
19	Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Science and Medicine, 2019, 6, e000270.	2.7	194
20	An epigenome-wide association study of total serum immunoglobulin E concentration. Nature, 2015, 520, 670-674.	27.8	193
21	The type I interferon system in the development of lupus. Seminars in Immunology, 2011, 23, 113-121.	5.6	188
22	A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Human Molecular Genetics, 2008, 17, 2868-2876.	2.9	183
23	Genome-wide DNA methylation analysis in multiple tissues in primary Sj¶gren's syndrome reveals regulatory effects at interferon-induced genes. Annals of the Rheumatic Diseases, 2016, 75, 2029-2036.	0.9	180
24	Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Human Molecular Genetics, 2008, 17, 872-881.	2.9	173
25	Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome. Genes and Immunity, 2009, 10, 68-76.	4.1	152
26	The Combination of Apoptotic U937 Cells and Lupus IgG Is a Potent IFN-α Inducer. Journal of Immunology, 2000, 165, 3519-3526.	0.8	150
27	Cytokines as therapeutic targets in SLE. Nature Reviews Rheumatology, 2010, 6, 339-347.	8.0	143
28	DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2018, 77, 736-743.	0.9	135
29	Systemic lupus erythematosus and the type I interferon system. Arthritis Research, 2003, 5, 68.	2.0	132
30	Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. Nature Medicine, 2021, 27, 668-676.	30.7	120
31	Role of Natural Interferon-α Producing Cells (Plasmacytoid Dendritic Cells) in Autoimmunity. Autoimmunity, 2003, 36, 463-472.	2.6	112
32	Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE. European Journal of Immunology, 2009, 39, 2925-2935.	2.9	107
33	A single nucleotide polymorphism in the <i>NCF1</i> gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 1607-1613.	0.9	103
34	Type I interferon and lupus. Current Opinion in Rheumatology, 2009, 21, 471-477.	4.3	100
35	The natural interferon-α producing cells in systemic lupus erythematosus. Human Immunology, 2002, 63, 1181-1193.	2.4	99
36	Role of interferons in SLE. Best Practice and Research in Clinical Rheumatology, 2017, 31, 415-428.	3.3	99

#	Article	IF	CITATIONS
37	The type I interferon system in the etiopathogenesis of autoimmune diseases. Upsala Journal of Medical Sciences, 2011, 116, 227-237.	0.9	96
38	Systemic Lupus Erythematosus – A Disease with A Dysregulated Type I Interferon System. Scandinavian Journal of Immunology, 2015, 82, 199-207.	2.7	91
39	Type I interferons in host defence and inflammatory diseases. Lupus Science and Medicine, 2019, 6, e000336.	2.7	91
40	Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis. PLoS ONE, 2013, 8, e84450.	2.5	88
41	Characterization of functional methylomes by next-generation capture sequencing identifies novel disease-associated variants. Nature Communications, 2015, 6, 7211.	12.8	84
42	IFN-α Production by Plasmacytoid Dendritic Cells Stimulated with RNA-Containing Immune Complexes Is Promoted by NK Cells via MIP-1β and LFA-1. Journal of Immunology, 2011, 186, 5085-5094.	0.8	80
43	Interferonâ€Î± mediates suppression of Câ€reactive protein: Explanation for muted Câ€reactive protein response in lupus flares?. Arthritis and Rheumatism, 2009, 60, 3755-3760.	6.7	78
44	High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 363-369.	0.9	76
45	The <i>STAT4</i> SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE. Annals of the Rheumatic Diseases, 2018, 77, 1070-1077.	0.9	74
46	Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted α-Enolase T Cell Epitope in Rheumatoid Arthritis. Frontiers in Immunology, 2016, 7, 494.	4.8	73
47	Transcription profiling of peripheral B cells in antibodyâ€positive primary Sjögren's syndrome reveals upregulated expression of <i>CX3CR1</i> and a type I and type II interferon signature. Scandinavian Journal of Immunology, 2018, 87, e12662.	2.7	72
48	An update on the role of type I interferons in systemic lupus erythematosus and Sjögren's syndrome. Current Opinion in Rheumatology, 2018, 30, 471-481.	4.3	70
49	A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2010, 69, 834-840.	0.9	68
50	Cause and consequences of the activated type I interferon system in SLE. Journal of Molecular Medicine, 2016, 94, 1103-1110.	3.9	65
51	Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. Human Genetics, 2019, 138, 141-150.	3.8	63
52	Disease Mechanisms in Rheumatology—Tools and Pathways: Plasmacytoid Dendritic Cells and Their Role in Autoimmune Rheumatic Diseases. Arthritis and Rheumatism, 2013, 65, 853-863.	6.7	62
53	Systemic lupus erythematosus: still a challenge for physicians. Journal of Internal Medicine, 2017, 281, 52-64.	6.0	61
54	ldentification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. PLoS Genetics, 2017, 13, e1006820.	3.5	60

#	Article	IF	CITATIONS
55	Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1363-1370.	0.9	60
56	The importance of the type I interferon system in autoimmunity. Clinical and Experimental Rheumatology, 2016, 34, 21-4.	0.8	57
57	Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor. Arthritis Research and Therapy, 2018, 20, 238.	3.5	56
58	Sex differences in clinical presentation of systemic lupus erythematosus. Biology of Sex Differences, 2019, 10, 60.	4.1	55
59	Novel risk genes for systemic lupus erythematosus predicted by random forest classification. Scientific Reports, 2017, 7, 6236.	3.3	54
60	B lymphocytes enhance interferonâ€Î± production by plasmacytoid dendritic cells. Arthritis and Rheumatism, 2012, 64, 3409-3419.	6.7	52
61	HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2013, 72, 1018-1025.	0.9	49
62	Allele-specific transcription factor binding to common and rare variants associated with disease and gene expression. Human Genetics, 2016, 135, 485-497.	3.8	45
63	Activated T cells enhance interferon- $\hat{I}\pm$ production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. Annals of the Rheumatic Diseases, 2016, 75, 1728-1734.	0.9	44
64	Potential role of IFNÎ \pm in adult lupus. Arthritis Research and Therapy, 2010, 12, S3.	3.5	43
65	Memory T cells specific to citrullinated $\hat{I}\pm$ -enolase are enriched in the rheumatic joint. Journal of Autoimmunity, 2018, 92, 47-56.	6.5	43
66	Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 1063-1069.	0.9	41
67	Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases. Frontiers in Immunology, 2019, 10, 2136.	4.8	41
68	Integration of Known DNA, RNA and Protein Biomarkers Provides Prediction of Anti-TNF Response in Rheumatoid Arthritis: Results from the COMBINE Study. Molecular Medicine, 2016, 22, 322-328.	4.4	39
69	Case definitions in Swedish register data to identify systemic lupus erythematosus. BMJ Open, 2016, 6, e007769.	1.9	39
70	Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patients. Biology of Sex Differences, 2017, 8, 25.	4.1	39
71	Shared and Unique Patterns of DNA Methylation in Systemic Lupus Erythematosus and Primary Sjögren's Syndrome. Frontiers in Immunology, 2019, 10, 1686.	4.8	39
72	Extended exome sequencing identifies <i>BACH2</i> as a novel major risk locus for Addison's disease. Journal of Internal Medicine, 2016, 280, 595-608.	6.0	37

#	Article	IF	CITATIONS
73	Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Annals of the Rheumatic Diseases, 2021, 80, 109-117.	0.9	35
74	Epigenome data release: a participant-centered approach to privacy protection. Genome Biology, 2015, 16, 142.	8.8	34
75	IFN-Â production by plasmacytoid dendritic cell associations with polymorphisms in gene loci related to autoimmune and inflammatory diseases. Human Molecular Genetics, 2015, 24, 3571-3581.	2.9	33
76	EOMESâ€positive CD4 ⁺ TÂcells are increased in <i>PTPN22</i> (1858T) risk allele carriers. European Journal of Immunology, 2018, 48, 655-669.	2.9	33
77	Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS—evaluation of whole blood, plasma, and serum as sample matrices. Arthritis Research and Therapy, 2020, 22, 125.	3.5	31
78	Association of Serum Câ€Reactive Protein Levels With Lupus Disease Activity in the Absence of Measurable Interferonâ€i± and a Câ€Reactive Protein Gene Variant. Arthritis and Rheumatology, 2014, 66, 1568-1573.	5.6	30
79	NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 254-261.	0.9	30
80	T cells are influenced by a long non-coding RNA in the autoimmune associated PTPN2 locus. Journal of Autoimmunity, 2018, 90, 28-38.	6.5	29
81	Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus. Covariation with platelet activation and possible association with thrombosis. Arthritis and Rheumatism, 1997, 40, 2178-2186.	6.7	28
82	NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE. JCI Insight, 2021, 6, .	5.0	28
83	Immunoseq: the identification of functionally relevant variants through targeted capture and sequencing of active regulatory regions in human immune cells. BMC Medical Genomics, 2016, 9, 59.	1.5	26
84	C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205. Frontiers in Immunology, 2020, 11, 622326.	4.8	26
85	Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding <i>HLAâ€DRB1</i> Genotype Associations and Immunological and Clinical Manifestations. ACR Open Rheumatology, 2022, 4, 27-39.	2.1	25
86	Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Seminars in Arthritis and Rheumatism, 2016, 45, 684-690.	3.4	23
87	Common genetic variation in the autoimmune regulator (AIRE) locus is associated with autoimmune Addison's disease in Sweden. Scientific Reports, 2018, 8, 8395.	3.3	22
88	Allelic expression mapping across cellular lineages to establish impact of nonâ€coding <scp>SNP</scp> s. Molecular Systems Biology, 2014, 10, 754.	7.2	21
89	Functional Antiâ€CD94/NKG2A and Antiâ€CD94/NKG2C Autoantibodies in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 1000-1011.	5.6	21
90	Multi-HLA class II tetramer analyses of citrulline-reactive T cells and early treatment response in rheumatoid arthritis. BMC Immunology, 2020, 21, 27.	2.2	20

#	Article	IF	CITATIONS
91	Plasmacytoid dendritic cells and RNA-containing immune complexes drive expansion of peripheral B cell subsets with an SLE-like phenotype. PLoS ONE, 2017, 12, e0183946.	2.5	20
92	DNA methylome analysis of acute lymphoblastic leukemia cells reveals stochastic <i>de novo</i> DNA methylation in CpG islands. Epigenomics, 2016, 8, 1367-1387.	2.1	19
93	Technological readiness and implementation of genomicâ€driven precision medicine for complex diseases. Journal of Internal Medicine, 2021, 290, 602-620.	6.0	18
94	Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 <i>in vitro</i> . Clinical and Experimental Immunology, 2017, 189, 83-91.	2.6	17
95	Complement <i>C4</i> Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases. Arthritis and Rheumatology, 2022, 74, 1440-1450.	5.6	17
96	Dissecting features of epigenetic variants underlying cardiometabolic risk using full-resolution epigenome profiling in regulatory elements. Nature Communications, 2019, 10, 1209.	12.8	16
97	Interferon-α enhances the IL-12-induced STAT4 activation selectively in carriers of the <i>STAT4</i> SLE risk allele rs7574865[T]. Annals of the Rheumatic Diseases, 2019, 78, 429-431.	0.9	16
98	Population-based study of patients with primary Sjögren's syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. Scandinavian Journal of Rheumatology, 2020, 49, 225-232.	1.1	16
99	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. Seminars in Arthritis and Rheumatism, 2020, 50, 1387-1393.	3.4	16
100	ILF2 and ILF3 are autoantigens in canine systemic autoimmune disease. Scientific Reports, 2018, 8, 4852.	3.3	15
101	Exploring rare and low-frequency variants in the Saguenay–Lac-Saint-Jean population identified genes associated with asthma and allergy traits. European Journal of Human Genetics, 2019, 27, 90-101.	2.8	15
102	OUP accepted manuscript. Rheumatology, 2021, 60, 837-848.	1.9	15
103	Immunogenetics in systemic lupus erythematosus: Transitioning from genetic associations to cellular effects. Scandinavian Journal of Immunology, 2020, 92, e12894.	2.7	15
104	Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjögren's syndrome. Scandinavian Journal of Rheumatology, 2019, 48, 207-212.	1.1	14
105	<i>De novo</i> lupus nephritis during treatment with belimumab. Rheumatology, 2021, 60, 4348-4354.	1.9	14
106	The regulation and pharmacological modulation of immune complex induced type III IFN production by plasmacytoid dendritic cells. Arthritis Research and Therapy, 2020, 22, 130.	3.5	14
107	IL-22 Binding Protein Promotes the Disease Process in Multiple Sclerosis. Journal of Immunology, 2019, 203, 888-898.	0.8	13
108	Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero. RMD Open, 2020, 6, e000989.	3.8	13

#	Article	IF	CITATIONS
109	DNA Methylation-Based Interferon Scores Associate With Sub-Phenotypes in Primary Sjögren's Syndrome. Frontiers in Immunology, 2021, 12, 702037.	4.8	13
110	A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. European Journal of Human Genetics, 2019, 27, 432-441.	2.8	12
111	Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 688753.	4.8	12
112	Function of multiple sclerosis-protective HLA class I alleles revealed by genome-wide protein-quantitative trait loci mapping of interferon signalling. PLoS Genetics, 2020, 16, e1009199.	3.5	12
113	Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. Frontiers in Immunology, 2019, 10, 1029.	4.8	11
114	Interaction between the <i>STAT4</i> rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 1183-1189.	0.9	10
115	Haplotype-Specific Expression Analysis of MHC Class II Genes in Healthy Individuals and Rheumatoid Arthritis Patients. Frontiers in Immunology, 2021, 12, 707217.	4.8	10
116	Variants in BANK1 are associated with lupus nephritis of European ancestry. Genes and Immunity, 2021, 22, 194-202.	4.1	9
117	Identification and functional characterization of a novel susceptibility locus for small vessel vasculitis with MPO-ANCA. Rheumatology, 2022, 61, 3461-3470.	1.9	8
118	Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis. Annals of the Rheumatic Diseases, 2021, 80, 404-406.	0.9	7
119	Contribution of Rare Genetic Variation to Disease Susceptibility in a Large Scandinavian Myositis Cohort. Arthritis and Rheumatology, 2022, 74, 342-352.	5.6	7
120	Genetic variants at the <i>RTP4/MASP1</i> locus are associated with fatigue in Scandinavian patients with primary Sjögren's syndrome. RMD Open, 2021, 7, e001832.	3.8	7
121	Contributions of de novo variants to systemic lupus erythematosus. European Journal of Human Genetics, 2021, 29, 184-193.	2.8	6
122	Identification of endothelin-converting enzyme-2 as an autoantigen in autoimmune polyendocrine syndrome type 1. Autoimmunity, 2017, 50, 223-231.	2.6	5
123	Activation of plasmacytoid dendritic cells and B cells with two structurally different Tollâ€like receptor 7 agonists. Scandinavian Journal of Immunology, 2020, 91, e12880.	2.7	5
124	A case of systemic lupus erythematosus with C1q deficiency, increased serum interferon-α levels and high serum interferogenic activity. Rheumatology, 2019, 58, 918-919.	1.9	4
125	Biomarkers: to be or not to be. Annals of the Rheumatic Diseases, 2020, 79, e8-e8.	0.9	3
126	S4D:5â€Targeted next-generation sequencing suggests novel risk loci in juvenile onset systemic lupus		9

erythematosus., 2018,,.

#	Article	IF	CITATIONS
127	Learning from similarities between vaccine responses and SLE. Nature Reviews Rheumatology, 2020, 16, 355-356.	8.0	2
128	Association of Protective HLA-A With HLA-Bâ^—27 Positive Ankylosing Spondylitis. Frontiers in Genetics, 2021, 12, 659042.	2.3	2
129	Association of <i>STAT4</i> , <i>IRF5</i> and <i>BLK</i> polymorphisms with severity and outcome in lupus nephritis. Annals of the Rheumatic Diseases, 2012, 71, A55.1-A55.	0.9	1
130	S4D:6â€Sle comprises four immune-phenotypes, which differ regarding hla-drb1 and clinical associations. , 2018, , .		1
131	S4A:5â€High genetic risk score is associated with organ damage in systemic lupus erythematosus. , 2018, ,		1
132	207â€A high genetic risk score is associated with early disease onset, organ damage and decreased survival in systemic lupus erythematosus. , 2019, , .		1
133	P86â€The NCF1–339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. , 2020, , .		1
134	SSA and SSB antibodies are important in the formation of circulating immune complexes in SLE. Annals of the Rheumatic Diseases, 2010, 69, A6-A6.	0.9	0
135	Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE. Annals of the Rheumatic Diseases, 2011, 70, A60-A61.	0.9	0
136	IgG glycan hydrolysis by EndoS diminishes the pro-inflammatory properties of immune complexes from patients with SLE – a possible new treatment?. Annals of the Rheumatic Diseases, 2012, 71, A1.2-A1.	0.9	0
137	SAT0232â€Lymphoma in patients with primary sjögren's syndrome: A population-based study of lymphom subtypes, risk factors and survival. Annals of the Rheumatic Diseases, 2013, 71, 550.2-550.	^a 0.9	0
138	A10.20â€On the Origin of the Type I Interferon Activity in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A79.1-A79.	0.9	0
139	THU0167â€Evaluation of two assays for antiphospholipid antibodies in 712 SLE patients; clinical associations depend on isotypes and cut-off levels. Annals of the Rheumatic Diseases, 2013, 71, 212.2-212.	0.9	Ο
140	FRI0172â€Utility of Swedish Register Data in Classifying Systemic Lupus. Annals of the Rheumatic Diseases, 2014, 73, 444.2-444.	0.9	0
141	01.15â€Type I IFN system activation in newborns exposed to anti-ro/ssa autoantibodies in utero. , 2017, , .		0
142	237â€Ischaemic stroke in systemic lupus erythematosus, -distribution of subtypes and a risk genotype in the stat4 gene. , 2017, , .		0
143	02.09â€Identification of a novel pro-inflammatory T cell epitope from his-trna-synthetase associated with interstitial lung disease in anti-jo-1 positive patients. , 2017, , .		0
144	O23â€Identification of protein-quantitative trait loci (pQTLs) in the interferon signalling pathway. , 2020, , .		0

#	Article	IF	CITATIONS
145	POS0370â€TYPE I INTERFERON PATHWAY ASSAYS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES - SYSTEMATIC LITERATURE REVIEW (SLR) AND DEVELOPMENT OF CONSENSUS TERMINOLOGY FROM A EULAR TASKFORCE. Annals of the Rheumatic Diseases, 2021, 80, 415-415.	0.9	0
146	THU0004â€Activated Plasmacytoid Dendritic Cells (PDCS) Alter The Composition of The Blood B Cell Subsets. Annals of the Rheumatic Diseases, 2016, 75, 179.1-179.	0.9	0